Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Amino Acid Sequence
Animals
Biological Transport
/ drug effects
Cell Line, Tumor
Drug Stability
Female
Gastrins
/ chemistry
Heterocyclic Compounds, 1-Ring
/ chemistry
Humans
Lutetium
Mice
Positron Emission Tomography Computed Tomography
Protease Inhibitors
/ pharmacology
Radioisotopes
Receptor, Cholecystokinin B
/ metabolism
Single Photon Emission Computed Tomography Computed Tomography
Tissue Distribution
/ drug effects
177Lu-DOTA-PP-F11N
cholecystokinin-2 receptor
gastrin
medullary thyroid cancer
peptide receptor radionuclide therapy
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
04
01
2018
accepted:
29
06
2018
pubmed:
14
7
2018
medline:
28
10
2019
entrez:
14
7
2018
Statut:
ppublish
Résumé
Patients with metastatic medullary thyroid cancer (MTC) have limited systemic treatment options. The use of radiolabeled gastrin analogs targeting the cholecystokinin-2 receptor (CCK2R) is an attractive approach. However, their therapeutic efficacy is presumably decreased by their enzymatic degradation in vivo. We aimed to investigate whether the chemically stabilized analog
Identifiants
pubmed: 30002107
pii: jnumed.118.207845
doi: 10.2967/jnumed.118.207845
doi:
Substances chimiques
Gastrins
0
Heterocyclic Compounds, 1-Ring
0
Protease Inhibitors
0
Radioisotopes
0
Receptor, Cholecystokinin B
0
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1HTE449DGZ
minigastrin
262J9O2552
Lutetium
5H0DOZ21UJ
Lutetium-177
BRH40Y9V1Q
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-399Informations de copyright
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.